In this regard, it has been hypothesized that part of the clinical and prognostic benefits of the treatment with drugs that inhibit the renin–angiotensin–aldosterone system is attributable to the slight increase in potassium levels [34,41], since this reduces the incidence of hypokalemia and hence the risk of sudden cardiac death. This evidence concerns the gene REN and Hypokalemia.